Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company plans to issue a pre-market press release and conduct a conference call and webcast on Tuesday, September 7, 2021, to discuss interim clinical data from an ongoing Phase 2a positron emission tomography (PET) imaging trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF).
The Company will host a conference call and webcast at 8:00 a.m. ET on Tuesday, September 7th to discuss this update. The link to the webcast of the conference call will be posted in the Events & Presentations section of the Company’s website. The conference call may also be accessed by dialing (833) 519-1340 (domestic) or (914) 800-3902 (international) five minutes prior to the start of the call and providing the passcode 6186023. An archived replay will be accessible for 90 days following the event.
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.